{
    "nct_id": "NCT00236431",
    "title": "A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2011-06-06",
    "description_brief": "The purpose of this study is to evaluate the efficacy and safety of galantamine treatment in patients with mild cognitive impairment.",
    "description_detailed": "This is an international, multicenter, double-blind, randomized, placebo-controlled trial. Patients with mild cognitive impairment (MCI) who are clinically at risk for development of Alzheimer's disease will be treated for 24 months with either placebo or galantamine hydrobromide. Memory and overall clinical improvement will be evaluated using the Alzheimer's Disease Assessment Scale with cognitive subscale adapted to MCI (ADAS-cog/MCI) and the Clinical Dementia Rating Sum of the Boxes (CDR-SB). Overall functional skills and the severity of dementia will be assessed with the Clinical Dementia Rating Sum of the Boxes (CDR-SB) and the overall Clinical Dementia Rating (CDR) score. Additional assessments include the Digit Symbol Substitution Test (DSST) to measure attention. Safety will be assessed using adverse event reports, vital signs, laboratory parameters, physical examination, and electrocardiogram. The study hypothesis is that treatment with galantamine will be well tolerated and, compared with placebo, will significantly improve the signs and symptoms associated with mild cognitive impairment in patients who are considered likely to develop Alzheimer's disease. Galantamine hydrobromide immediate-release tablets (4, 8, or 12 milligrams), taken by mouth 2 times daily: 8mg/day for 4 weeks, 16mg/day for 4 weeks, then increased to 24mg/day for the remainder of the 24-month trial. Doses may be reduced at investigator's discretion after 12 weeks.",
    "phase": [
        "PHASE3"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "galantamine (Razadyne / Reminyl)"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The trial tests galantamine, which is a small-molecule acetylcholinesterase inhibitor that also allosterically potentiates nicotinic acetylcholine receptors; its clinically intended effect is symptomatic improvement of cognition (memory/attention) rather than targeting amyloid or tau pathology. \ue200cite\ue202turn0search0\ue202turn0search1\ue202turn0search4\ue201.",
        "Act: Extracted key details from the description \u2014 intervention: galantamine (oral small-molecule drug); trial design: randomized, double-blind, placebo-controlled in patients with MCI at risk for Alzheimer\u2019s disease; intended effect in this context: improve/maintain cognitive function and global measures. \ue200cite\ue202turn0search0\ue202turn0search4\ue201.",
        "Web search results (selected, supporting the above): 1) \"Galantamine in Alzheimer's disease\" (review summarizing galantamine\u2019s AChE inhibition and clinical symptomatic benefits). \ue200cite\ue202turn0search0\ue201. 2) \"Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR\" (evidence of nicotinic receptor potentiation\u2014dual mechanism). \ue200cite\ue202turn0search1\ue201. 3) \"Current status and new developments with galantamine in the treatment of Alzheimer's disease\" (clinical program showing cognitive and functional effects). \ue200cite\ue202turn0search4\ue201. 4) \"GALANTAMINE: A REVIEW OF ITS USE IN ALZHEIMER'S DISEASE AND VASCULAR DEMENTIA\" (summary of clinical efficacy and mechanism). \ue200cite\ue202turn0search2\ue201. 5) \"The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission...\" (mechanistic electrophysiology support). \ue200cite\ue202turn0search6\ue201.",
        "Reflect: Classification check \u2014 galantamine is a small-molecule symptomatic cognitive enhancer (cholinergic augmenter), not a biologic (no monoclonal antibody or vaccine) and not primarily intended as a disease-modifying anti-amyloid or anti-tau agent; it therefore matches the \"cognitive enhancer\" category. No strong evidence in the trial title/description that the drug is being tested to modify underlying AD pathology or to primarily treat neuropsychiatric symptoms, so alternative categories (disease-targeted biologic/small-molecule or neuropsychiatric symptom improvement) are not appropriate. \ue200cite\ue202turn0search0\ue202turn0search1\ue201."
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The trial tests galantamine, a small-molecule cholinergic cognitive enhancer whose primary approved mechanism is reversible inhibition of acetylcholinesterase (increasing synaptic acetylcholine) and which also has reported allosteric potentiating effects on nicotinic acetylcholine receptors. The intervention therefore modulates cholinergic neurotransmission/receptors rather than targeting amyloid, tau, inflammation, or other disease-modifying pathways. \ue200cite\ue202turn1search7\ue202turn1search1\ue201.",
        "Act: Extracted details \u2014 intervention: galantamine (Razadyne/Reminyl), oral small-molecule AChE inhibitor with nicotinic receptor allosteric potentiation; clinical aim in this trial: symptomatic cognitive enhancement in MCI at risk for AD (not described as an anti-amyloid or anti-tau disease-modifying therapy). Based on these facts, the most specific CADRO match is D) Neurotransmitter Receptors. \ue200cite\ue202turn0search1\ue202turn1search6\ue201.",
        "Reflect: Confirmed that galantamine\u2019s mechanism and clinical intent align with CADRO\u2019s Neurotransmitter Receptors category (cholinergic system / nicotinic receptor modulation). Alternative categories (e.g., M) Synaptic Plasticity/Neuroprotection or R) Multi-target are less specific because the trial is clearly testing symptomatic cholinergic augmentation; 'T) Other' is inappropriate because this is a therapeutic intervention with a known neurotransmitter-receptor mechanism. Key supporting web sources are listed below. \ue200cite\ue202turn0search0\ue202turn0search3\ue201.",
        "Web search results (selected, supporting the above): 1) Cochrane review summarizing galantamine\u2019s symptomatic benefits in AD and limited evidence in MCI. \ue200cite\ue202turn0search0\ue201. 2) PNAS mechanistic paper describing galantamine\u2019s AChE inhibition and effects on nicotinic receptors. \ue200cite\ue202turn0search3\ue201. 3) PubMed reports that galantamine is an allosterically potentiating ligand of human alpha4/beta2 and other nAChR subtypes. \ue200cite\ue202turn1search1\ue201. 4) FDA/prescribing information indicating galantamine (Razadyne) is a cholinesterase inhibitor indicated for symptomatic treatment of mild\u2013moderate AD. \ue200cite\ue202turn1search7\ue202turn1search4\ue201. 5) Reviews summarizing in vivo evidence that nicotinic potentiation may contribute to galantamine\u2019s clinical profile. \ue200cite\ue202turn1search6\ue201."
    ]
}